The registered dose of dupilumab for adult atopic dermatitis (AD) patients is 300mg every other week (Q2W). However, it is unknown whether serum dupilumab levels are associated with treatment response or side effects. Our objectives were to evaluate serum dupilumab levels after 16 weeks of treatment in patients with AD, and to explore its association with treatment response and side effects. This prospective cohort study consecutively included adult AD patients treated with dupilumab 300mg Q2W for at least 16 weeks. At week 16 and 52 disease severity was assessed by EASI-score and side effects were recorded. At 16-weeks the association between serum dupilumab levels and treatment response was analysed. Multivariate logistic regression modelling was used to determine the prediction of response (EASI90; EASI≤7) and side effects after 52-weeks, with serum dupilumab levels at 16 weeks. A total of 295 patients were included with median drug level of 86.6 μg/mL (IQR=64.6-110.0; range 10.1-382.0) after 16 weeks of treatment. No significant differences were found in serum dupilumab levels between responder statuses ( This real-world study in AD patients found a broad range of serum dupilumab levels at 16 weeks of treatment, with no association to treatment response and side effects during first year of treatment.

ESDR126 - Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients

The scientific meeting of the European Society for Dermatological Research (ESDR) is held yearly, usually in September. With an international attendance of more than 1000 skin scientists from around the globe, the four-day event includes short oral presentations from peer-reviewed abstracts, keynote lectures from international experts, sponsored symposia, satellite programs, educational events as well as an important focus on posters, networking and building collaborations amongst scientists. For more information about this year’s meeting visit our website.